💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Urokinase

CHEMBL1201420 Phase 4 Aprovado Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Urokinase (urokinase-type plasminogen activator, u-PA) is a serine protease enzyme that cleaves plasminogen to plasmin, which in turn degrades fibrin clots, making it a thrombolytic agent. It is used for the treatment of acute massive pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, and to restore patency of occluded intravenous catheters. Unlike tissue plasminogen activator (t-PA), urokinase is non-fibrin-selective and produces systemic fibrinolysis.

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Non-Small Cell Lung Cancer Oncology Stroke Deep Vein Thrombosis / Pulmonary Embolism Breast Cancer Prostate Cancer Colorectal Cancer

Mecanismo de Ação

Activates plasminogen to plasmin, the enzyme that degrades fibrin clots. This restores blood flow through occluded vessels by dissolving pathological thrombi.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Activates plasminogen to plasmin, the enzyme that degrades fibrin clots. This restores blood flow through occluded vessels by dissolving pathological thrombi.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Urokinase (urokinase-type plasminogen activator, u-PA) is a serine protease enzyme that cleaves plasminogen to plasmin, which in turn degrades fibrin clots, making it a thrombolytic agent. It is used for the treatment of acute massive pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, and to restore patency of occluded intravenous catheters. Unlike tissue plasminogen activator (t-PA), urokinase is non-fibrin-selective and produces systemic fibrinolysis.

Activates plasminogen to plasmin, the enzyme that degrades fibrin clots. This restores blood flow through occluded vessels by dissolving pathological thrombi.

Yes, Urokinase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201420. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.